The Things That Still Run You

ION PT Network Lands Strategic Investment From 5CP

Joseph Noel had options. He picked the investor that understood why a physical therapist belongs between the referral and the outcome.

That decision explains more about ION PT Network than a transaction headline can.

5th Century Partners has made a strategic investment in ION PT Network, the clinician-managed physical therapy and rehabilitation network Joseph Noel founded in 2017 for the workers' compensation market. Financial terms were not disclosed, and Joseph Noel will remain founder and CEO.

ION coordinates treatment through independent providers, but the useful distinction is who owns the case. Each referral receives a dedicated clinical case owner who works across the injured worker, claims adjuster, and treating provider. More than half of ION's staff are licensed therapists, according to the announcement.

That structure turns coordination into clinical work. A referral does not move through the system as a scheduling ticket. Someone with treatment experience remains responsible for seeing how the parts fit together.

For a payer or employer, that means the promise is not simply more provider access. It is clearer accountability around utilization, communication, and recovery. For an injured worker, it means fewer handoffs without an obvious owner.

Marques Torbert, managing partner at 5th Century Partners, described ION's clinical-oversight model as difficult to replicate. Will Smith, partner at the firm, said the work will include refining ION's commercial strategy while protecting the model that already earns payer trust.

That last part matters. Growth capital can buy reach, systems, and sales capacity. It can also create pressure to standardize the exact judgment that made a healthcare-services company valuable.

ION is adding operating weight for the next phase. Sara Mulick recently joined as CRO, and Alina Schreiber joined as CFO. The company plans to keep its brand and expand service to more payers, third-party administrators, employers, self-insured organizations, and injured workers across the country.

The amount is undisclosed, so the useful signal is not the size of the check. It is the fit between a founder protecting a clinician-led operating model and an investor committing to scale around it.

ION now has to make that fit visible case by case. Every new payer relationship will add volume to the network. The company's opportunity is to let that volume strengthen the clinical handoff instead of turning it into another layer of administration.

Deeper Analysis 👇

https://devcuration.com/articles/ion-pt-network-5cp-strategic-investment

Mesa Quantum Raises $11.8M for GPS-Independent Timing

Making atoms react is the science. Making the hardware survive a factory, a field deployment, and a procurement cycle is the company.

Mesa Quantum raised $11.8M to cross that distance. Playground Global led; DCVC and J2 Ventures joined, according to Tectonic Defense. Mesa now reports nearly $16M in venture funding, separate from more than $5M in U.S. government awards.

Mesa did not disclose a round stage. The job matters more. Co-founder and CEO Sristy Agrawal and co-founder and CTO Wale Lawal are moving from component development and research demonstrations toward integrated, ruggedized timing and navigation systems that customers can test outside a lab.

GPS makes position visible, but precise time sits underneath it. Data centers, grids, markets, satellites, and autonomous platforms need machines to agree on the clock. When signals are jammed, spoofed, or blocked, that agreement erodes before the equipment stops.

Mesa Quantum builds around vapor cells, tiny glass containers holding vaporized atoms. Changes in laser-light absorption can reveal acceleration, rotation, magnetic fields, or, when the atoms are isolated, provide a stable time reference. The commercial problem is turning that sensitivity into low-size, low-power hardware that can be made repeatedly and affordably.

That is where this capital goes. Mesa Quantum says it will fund final product assembly, system optimization, customer validation, and early deployment of field-ready systems. The company is also expanding characterization and production-readiness work in New Mexico, including collaboration with Sandia National Laboratories on quantum-optimized VCSELs and photonic integrated circuits.

Playground is underwriting the manufacturing handoff. DCVC and J2 are joining a bet that GPS resilience becomes a component and supply-chain market, not only a defense-research program. The same timing problem moves through drone swarms, LEO satellites, M-Code receivers, data centers, telecom, and power infrastructure, even when the tolerance for failure changes by customer.

Mesa Quantum still has to prove repeatable field performance, production economics, and customer adoption. The company has disclosed prototypes and research demonstrations, not a roster of scaled deployments. That gap is exactly why the financing matters: technical sensitivity now has to become hardware that procurement teams can qualify, operators can trust, and factories can keep producing after the first impressive demo has left the room.

Deeper Analysis 👇 https://devcuration.com/articles/mesa-quantum-raises-11-8m-for-gps-independent-timing

Solcoa Raises $75M to Scale U.S. Rare Earth Metals

America's rare earth strategy has mines on one side and magnet factories on the other. The metal between them is still mostly made in China.

That conversion is metallization. It turns refined rare earth oxides into the metal used in the high-performance magnets inside EVs, robots, wind turbines, speakers, and defense systems. China controls 95% of that capacity, according to Solcoa Industries.

Solcoa Industries has secured $75M to scale an American alternative. The package includes $45M in equity led by Bain Capital Ventures, with Gigascale Capital, Long Journey, Felicis, Dylan Field, and other technology and defense leaders participating. J.P. Morgan anchored another $30M in debt and equipment financing.

That split matters. Hooman Reza Nezhad and Artem Iurkovskyi are building Solcoa One, a 500-tonne-per-year Nevada plant, expanding reactor manufacturing in Alameda, and hiring the engineers who have to turn chemistry into repeatable output.

Hooman Reza Nezhad, CEO, and Artem Iurkovskyi, CTO, founded Solcoa around a different approach to metalmaking. The company designs its own halide-free chemistry and modular reactors. Solcoa says the process is faster, cleaner, less energy-intensive, and cheaper than conventional molten-salt electrolysis. Those claims still have to survive scale.

Today, Solcoa reports more than 10 tonnes of annual magnet-grade metal capacity in Alameda. Solcoa One is designed for 500 tonnes, enough NdPr for as many as 1 million EVs, with commissioning planned for July 2027.

The date matters. Starting January 1, 2027, U.S. defense sourcing restrictions extend across covered magnet supply chains, including rare earths mined, refined, separated, melted, or produced in China, Russia, Iran, or North Korea, subject to exceptions.

A Western-made magnet can still carry Chinese dependency upstream. Mines and magnet factories do not close the metallization gap.

That is the industrial handoff Solcoa is trying to own.

The equity gives Solcoa room to absorb the surprises between pilot and plant. The equipment financing puts capital against the physical system. Together, they turn a rare earth thesis into a commissioning schedule.

The next proof will not be another announcement. It will be consistent magnet-grade output, qualified by customers, moving from Alameda into a Nevada plant while the regulatory clock keeps moving.

America has spent years funding mines, separation, and magnet capacity. Solcoa is building the step that has to connect them.

Deeper Analysis 👇

https://devcuration.com/articles/solcoa-industries-raises-75m-in-funding

HIFI Raises $37M for Tokenized Money Infrastructure

Most financial products still move money in shifts. Bank windows, settlement delays, and disconnected ledgers keep deciding when value actually arrives.

HIFI raised a $37M Series A to make that machinery behave more like software. Left Lane Capital led the round, with Tether participating according to returning investor Antler. Left Lane Managing Partner Matt Miller is joining HIFI’s board.

Co-founders Zach Walsh, CEO, and Mohamed “Mo” Afifi, COO, started the New York company in 2022 around one idea: payments, card spending, and capital-market settlement should not require 3 infrastructure stacks when each job ends with value moving between parties.

HIFI gives developers one API for stablecoins, bank rails, payment networks, programmable controls, compliance, and settlement. The company says it processes over $7B annually across 87 countries. Customers building on HIFI have onboarded more than 10,000 businesses and 200,000 individuals, while usage among existing customers grew more than 4x over 6 months.

The traction matters because stablecoins have graduated from crypto-market inventory into working capital. A supplier can be paid across borders. Treasury can move outside ordinary banking hours. A tokenized security can settle against tokenized cash without institutions reconciling after the fact.

That cleaner story still lands in a regulated, unforgiving business. HIFI is a financial technology company, not a bank. Its customers still depend on banking partners, licensing, identity checks, transaction monitoring, custody, liquidity, and local payout rails. Making money programmable puts those obligations inside the product.

HIFI has been testing that architecture where the consequences get serious. Its platform participated in DTCC’s July tokenized-asset work, supported a live repo transaction between DRW and Marex on the Canton Network, and now pairs its settlement layer with Visa Direct for stablecoin-funded payouts to eligible Visa cards.

The capital will fund more regulatory licenses, hiring in New York and selected international markets, and expansion from payments into cards and tokenized capital markets. Left Lane is backing HIFI’s attempt to own the handoff between programmable assets and institutions moving real money safely.

That handoff becomes the company now. Every new corridor, card product, and capital-market workflow adds another jurisdiction, counterparty, control, and exception that has to work when markets are open, banks are closed, and software still expects an answer.

Deeper Analysis 👇 https://devcuration.com/articles/hifi-raises-37m-for-tokenized-money-infrastructure

Aligned Modern Health Gets Arcventis Majority Investment

Patients rarely describe their problem as a category opportunity. They say the symptoms keep returning, the appointments feel disconnected, and the next step is still unclear.

Aligned Modern Health built around that frustration. The Chicago-founded company combines functional medicine, hormone health, chiropractic care, acupuncture, and virtual care. It now has a new majority investor for the difficult part: making personalized care work across more clinicians and states.

Arcventis Health Partners has made a majority growth investment in Aligned Modern Health. Harbour Point Capital will remain a meaningful investor. The amount and valuation were not disclosed, which keeps this story away from the usual scoreboard and closer to the operating wager.

The company says 100+ doctors, nurse practitioners, and clinicians support 15 Chicago-area clinics and telehealth in 20+ states. It accepts most major insurance for visits and bloodwork, widening access beyond a concierge-only model.

Virginia Materese, CEO of Aligned Modern Health, is using the partnership to push 4 connected priorities: national expansion, broader clinical offerings, a stronger digital patient experience, and larger provider and clinical teams.

Aligned Modern Health launched hormone replacement therapy in 2025 and added peptide therapy in 2026, expanding the clinical menu around its existing services.

The market will be tempted to read that as a menu expansion. The harder work is continuity. A telehealth appointment happens in the state where the patient is located, which means growth carries licensure, staffing, scope-of-practice, documentation, insurance, and clinical-oversight obligations into every new market.

That is where Arcventis enters. Fazeela Abdul Rashid and the firm are backing a healthcare-services platform at the point where local trust has to become a repeatable operating system. Harbour Point staying invested adds continuity from the previous growth chapter.

Brian Carey, Andrew Ingley, William Fiely, and Ryan O'Toole built the company from Chicago. Materese now has to make national scale feel less fragmented to patients than the system Aligned Modern Health is asking them to leave behind.

Capital can open states, recruit clinicians, and improve the digital front door. The judgment arrives in the quieter handoffs: whether the record follows the patient, the provider has enough context, and personalized care still feels personal.

Deeper Analysis 👇 https://devcuration.com/articles/aligned-modern-health-majority-investment-arcventis

Axio BioPharma Raises $2.4M for Manufacturing Data

A biologics program can spend 18 months and nearly $2M before anyone realizes the manufacturing answer was hiding in the wrong system.

That happened on a client program Justin Byers worked on before founding Axio BioPharma. The information needed to judge whether the drug could scale existed, but it was scattered across systems that did not carry the context forward.

Biopharma has digitized plenty. The awkward part begins when a program crosses a company line. A sponsor and its manufacturing partner may each have excellent systems, then technology transfer arrives with spreadsheets, mismatched terminology, and people rebuilding what the data meant.

Axio has raised a $2.4M pre-seed round from Elmstead Partners, Chisos Capital, Chemical Angel Network, and individual angel investors to work on that boundary. No lead investor or valuation was disclosed.

The Madison company pairs 2 businesses. Axio Forge is a research-grade monoclonal-antibody lab where the team sees how process data is produced and interpreted. Axio Lattice connects manufacturing information across companies while the underlying data stays in each organization's systems and ownership.

Rosetta is the translation layer. It maps terminology, structure, and context so information remains understandable across organizations. In regulated manufacturing, an AI answer has to bring its lineage and quality obligations with it. Available data is not useful when its meaning changed during transfer.

The capital will support Lattice deployments and Rosetta development. The first node operates at Forward BIOLABS, where Forge is based. Axio says deployment work will focus on technology transfer and investigations, 2 places where missing context becomes expensive.

Justin Byers is founder and CEO. Brian Staats, co-founder and CTO, brings more than 20 years in bioinformatics, data science, and engineering. One side understands how biologics work moves; the other understands how information can move without losing its meaning.

The evidence is early. Axio has not named its Lattice design partners, published deployment results, or quantified customer savings. A federated architecture still has to earn trust across security, quality, ownership, and governance boundaries.

The $2.4M round gives Axio room to take the idea out of its own lab and into those boundaries. Each deployment will test whether Rosetta can help sponsors and manufacturers spend less time reconstructing the past and more time deciding what the process should do next.

Deeper Analysis 👇 https://devcuration.com/articles/axio-biopharma-raises-2-4m-for-manufacturing-data

Everest Biolabs Receives $2.1M NIH Grant

Biomarker discovery can lose the answer before the mass spectrometer sees the sample.

Blood is crowded. A small group of abundant proteins consumes most of the analytical attention, while lower-abundance signals from the brain, heart, or a tumor can sit near the edge of detection. Extracellular vesicles carry molecular material from the cells that released them, but isolating those vesicles cleanly across hundreds or thousands of samples is where an elegant biological idea meets laboratory reality.

Everest Biolabs has announced a $2.1M NIH Small Business Innovation Research grant to work on that reality. The NIGMS Direct-to-Phase II project will fund automated, plate-based EV isolation and next-generation Apex columns designed to reduce the albumin, immunoglobulin, and lipoprotein contamination that can bury disease-relevant signals.

The accounting deserves precision. Everest announced $2.1M as the total grant value. NIH RePORTER lists $1,153,043 for the FY2026 budget year, with the project running through August 2028. The figures describe different funding periods.

Tal Gilboa, Everest Biolabs co-founder and Head of Research, is the project's principal investigator. George Daaboul, CEO and co-founder, and David Freedman, President, COO, and co-founder, are building around a method with a direct research lineage from David Walt's laboratory at the Wyss Institute.

The product logic is already visible. Ascent automates 1 to 8 column-based isolations. Summit is designed for 4 to 48 samples using plates or columns. Apex supplies the separation media, while Atlas supports quantification and purity assessment. Everest is not selling one clever component. It is assembling the sample-preparation stack that determines whether the downstream instrument receives biology or noise.

That makes throughput a reproducibility problem before it becomes a speed claim. A 48-sample run is useful only when sample 1 and sample 48 were treated consistently enough to compare. Scale magnifies every manual transfer, flow-rate difference, contaminant load, and recovery trade-off the workflow failed to control.

The grant does not establish a clinical diagnostic, regulatory approval, or market adoption. It funds the work needed to find out whether high yield, high purity, and automation can coexist across laboratories.

EV research already has ambition. Everest Biolabs is being paid to make the evidence travel farther than the expert who developed the protocol.

Deeper Analysis 👇 https://devcuration.com/articles/everest-biolabs-2-1m-nih-grant

Snag Raises $4M for Liquid Housing

Moving for the opportunity can happen in a week. Renting for it still asks people to prove that the next 12 months of work, income, and geography are already settled.

Selin Sonmez and Nikos Georgantas found the gap while building OneRoof, a social network for apartment buildings. Residents kept using the community to trade rooms, sublets, and lease takeovers. The product eventually shut down, but the behavior had already handed the founders their next company.

Snag has now raised a $4M Seed round led by Slow Ventures, with Precursor Ventures, Long Journey Ventures, Chamaeleon, Brian Kelly, and Sloane Stephens participating.

The funding is attached to sharp customer research. Gen Z renters, creators, students, and people with portfolio careers move through cities differently than the standard lease expects. They have built a parallel housing market across Instagram Stories, Facebook groups, group chats, and direct messages because the formal market moves slowly and often demands an employment profile that no longer describes them.

That workaround is fast. It is also where incomplete listings, uncertain identities, rushed payments, and beautifully lit scams get to enjoy the same interface.

Snag is trying to keep the speed while adding the parts informal channels forgot. The company says users can verify identities, run background and credit checks, hold video calls, and route payments through the platform. Its AI can answer questions from listing information, suggest the next step, build fuller listings from a few photos, and recommend pricing from comparable properties.

Snag says it generated roughly 90M organic TikTok views through about 10 creator accounts, with around one-third of growth coming from word of mouth. The company reports more than 4,500 New York listings and says an average listing finds a renter in 3 days. Those figures are company-reported, but they reveal the bet: housing discovery is starting to look like the media behavior around it.

Slow Ventures and the participating investors are financing more than a cleaner sublet search. They are backing the idea that mobility has become an operating condition for a wider class of renters, while verification, payments, supply, and local rules still have to work address by address.

The $4M gives Snag room to build around that handoff. The harder part will be turning trust borrowed from a friend, follower, or group chat into infrastructure that still feels fast when the marketplace reaches another building, landlord, and city.

Deeper Analysis 👇 https://devcuration.com/articles/snag-raises-4m-for-liquid-housing

Dash Dog Food Raises $1.5M for Fresh-Frozen Growth

Bobby Quirk spent a decade learning how meat supply chains earn trust for people. Then Maisy made the buying decision personal.

His dog could not audit a label, compare suppliers, or explain why a meal was not working. Quirk had to make the choice on her behalf.

That decision became DASH Dog Food. Now the fresh-frozen subscription brand has closed an oversubscribed $1.5M Seed round led by Voltage Ventures, with Western Technology Investment and individual investors from direct-to-consumer protein, cold-chain logistics, and retail participating.

Quirk was ButcherBox's first hire and later its VP of Operations. DASH grew from ButcherBox for Pets, separated in June 2025, and took its new name this June.

The inheritance matters. DASH is applying ButcherBox supplier relationships and sourcing discipline to dog food made with grass-fed beef or organic chicken. The company says its sous vide meals contain pre- and postbiotics and are formulated to meet AAFCO nutrient profiles.

DASH calls the standard “Table-Grade.” It is brand language, not a regulatory category, but the commercial idea is clear: make the sourcing decision visible.

After the spinout, DASH discontinued dry food and narrowed the company around fresh-frozen meals. The focus makes the brand easier to explain and execution harder to fake.

Fresh food brings manufacturing, formulation, fulfillment, and cold-chain pressure into every subscription. Premium ingredients may win the first order; consistency earns the next one.

DASH reports 130% revenue growth since separating, though it has not disclosed revenue, subscribers, retention, or acquisition economics. The Seed round will fund paid acquisition, redesigned packaging, and seafood and turkey recipes.

Roughly 10% is earmarked for formulation R&D. Recipe expansion only matters if nutrition, sourcing, production, and delivery keep moving together.

Voltage General Partner Marissa Bertorelli and ButcherBox founder and CEO Mike Salguero are joining the DASH board, connecting animal-health investing with DASH's operating roots.

APPA projects $69.7B in U.S. pet-food and treat sales in 2026. DASH has to prove better sourcing visibility can become durable subscription behavior.

Quirk started with one dog and an uncomfortable decision. The capital carries it into more kitchens, more proteins, and a supply chain that has to keep earning trust after the first box, in a category where every meal repeats the choice.

Deeper Analysis 👇 https://devcuration.com/articles/dash-dog-food-raises-1-5m-for-fresh-frozen-growth

Redefine Surgery Closes Pre-Seed, Reaches $10M Total

A surgical robot can hit a coordinate and still miss the lesson that made an expert surgeon choose it.

Peter Verrillo, Ignacio Tzoumas, and Stephen Potter are building Redefine Surgery around that gap. The company closed an oversubscribed Pre-Seed financing on September 24, bringing total capital raised to $10M.

That accounting matters. Redefine disclosed the total raised across its history, not the size of this closing. The new round is backed predominantly by surgeon investors, but the company did not name a lead, full syndicate, or valuation.

The people expected to use the system are helping finance and shape it. Redefine says its network includes more than 25 surgeon advisors, while many early investors are surgeons.

The platform combines computer vision, AI, and robotics for orthopedic surgery. Redefine says its trackerless vision system can register in seconds during early lab testing and reach about 1 mm and 1 degree of accuracy in key steps. Those are development metrics, not clinical clearance. The product remains under development, is not commercially available, and has not been cleared by the FDA.

That boundary is why the Catalyst OrthoScience partnership matters. Catalyst has joined as the founding partner for shoulder arthroplasty, connecting Redefine's technology to a specific implant category, procedure, and operating-room workflow.

The companies want to link preoperative planning, intraoperative guidance, workflow optimization, data capture, procedural analysis, and future assistive applications. They target up to 4x greater procedure-time efficiency and 10x lower technology cost, goals that still require clinical and economic proof.

Redefine is making a useful distinction in a market that loves skipping to autonomy. Its stated model keeps the surgeon in control while the system learns from anatomy, instrument movement, decisions, and outcomes. The ambition is not merely to navigate an implant. It is to build an intelligence layer that understands more of the procedure around it.

$10M gives Redefine room to turn that ambition into evidence. Surgeon participation can sharpen the system, and Catalyst can give it a focused clinical lane. Neither removes the burden of proving reliability, integrating into a live OR, clearing the regulatory path, and making the economics work.

The operating room will not reward AI for sounding intelligent. It will reward technology that earns trust while the surgeon remains responsible for every decision the machine helps inform.

Deeper Analysis 👇 https://devcuration.com/articles/redefine-surgery-pre-seed-10m-surgical-intelligence